trial · primary record
JNJ-77242113
Plaque Psoriasis
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 752 |
| Primary completion | 2027-08-20 |
| Primary endpoint | JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16 |
| Registry ID | NCT06934226 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:55:50.795Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06934226
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Jnj-77242113 · compound